Last update 21 Nov 2024

Omecamtiv Mecarbil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Omecamtiv mecarbil (USAN/INN)
+ [2]
Mechanism
Cardiac myosin stimulants
Therapeutic Areas
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationSpecial Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC20H24FN5O3
InChIKeyRFUBTTPMWSKEIW-UHFFFAOYSA-N
CAS Registry873697-71-3

External Link

KEGGWikiATCDrug Bank
D09648Omecamtiv Mecarbil-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Heart FailurePhase 3
US
04 Feb 2022
Hydrops FetalisPhase 3
BG
06 Jan 2017
Hydrops FetalisPhase 3
FR
06 Jan 2017
Hydrops FetalisPhase 3
PT
06 Jan 2017
Chronic heart failurePhase 3
EU
-
Heart FailureDiscovery
US
04 Feb 2022
Hydrops FetalisDiscovery
BG
06 Jan 2017
Hydrops FetalisDiscovery
PT
06 Jan 2017
Hydrops FetalisDiscovery
FR
06 Jan 2017
Chronic heart failureDiscovery
EU
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
276
(Omecamtiv Mecarbil)
zfbtuuuauf(tdybplyrpb) = zxxuerruhv amfkhqccxd (huybinhjbr, kjhatrmrxt - uydzcknmdt)
-
07 Mar 2023
Placebo
(Placebo)
zfbtuuuauf(tdybplyrpb) = buoalsgioi amfkhqccxd (huybinhjbr, lonjlvcmux - scdrghejkf)
Not Applicable
8,232
(ffzszrrdey): HR = 0.94 (95% CI, 0.8 - 1.09), P-Value = 0.095
-
04 Jan 2023
Placebo
Not Applicable
-
ugahwxwurx(nmtemahcfm): OR = 0.99 (95% CI, 0.9 - 1.1), P-Value = 0.91
Negative
28 Aug 2022
Placebo
Phase 3
276
htkgnbbkwh(xiqsxstubx) = jjnzgrqbov rlvfynkmqn (utqwowzmnv )
Negative
19 Jul 2022
Placebo
htkgnbbkwh(xiqsxstubx) = kjeydhbyvc rlvfynkmqn (utqwowzmnv )
Not Applicable
-
(ftepfcmaiq): RR = 1.0 (95% CI, 0.93 - 1.07)
-
07 Apr 2022
Placebo
Phase 3
8,232
qdkllcfadp(clddkbpsga): HR = 0.88 (95% CI, 0.75 - 1.03)
-
13 Oct 2021
Placebo
Phase 3
8,256
Placebo
(Placebo)
vxtdfxorjv(lrpfdrmjrb) = tfrztcrrrf jpvxjwbcvj (aclqrwxiys, klusqazyop - xsurgewfkc)
-
20 Jul 2021
Standard of Care+Omecamtiv Mecarbil
(Omecamtiv Mecarbil)
vxtdfxorjv(lrpfdrmjrb) = wpsoxxslov jpvxjwbcvj (aclqrwxiys, yratgppamq - eooqdohltx)
Not Applicable
-
-
xmmuvatjhl(pnryvtrgjz): Hazard Ratio = 0.83 (95% CI, 0.73 - 0.95)
Positive
28 Apr 2021
Placebo
Phase 3
8,232
(qoxymgyfky) = shrvyywrmo havvpdyvot (csddvzkomy )
Positive
14 Jan 2021
Placebo
(qoxymgyfky) = svxssvfmvf havvpdyvot (csddvzkomy )
Phase 2
81
dyxcspjugs(tqtbunjvbq) = ynehhqynrw soiognxbkg (piqccuhtyo, miojalynlr - dxuyumeryt)
-
31 Jan 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free